Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03941964 · ClinicalTrials.gov registry record · Phase 3

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

A Phase 3 study of Cancer and Acute Myeloid Leukemia (AML), sponsored by AbbVie.

Completed
Registry status
Phase 3
Development phase
60
Enrollment target
16
Study locations

NCT03941964 is a Phase 3 study of Cancer and Acute Myeloid Leukemia (AML) that has completed, run by AbbVie. The registered enrollment target is 60 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 16 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03941964, a Phase 3 study of Cancer and Acute Myeloid Leukemia (AML), has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 3
Development phase
60 participants
Enrollment target
16
Study locations

Study Summary

A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with AML who are ineligible for intensive chemotherapy.

Conditions Studied

Cancer Acute Myeloid Leukemia (AML)

Interventions

  • DRUG Venetoclax
  • DRUG Azacitidine
  • DRUG Decitabine

Study Locations (16)

Texas

  • Texas Oncology - Austin Midtown /ID# 212780 - Austin
  • Texas Oncology - Medical City Dallas /ID# 211503 - Dallas
  • Texas Transplant Institute /ID# 213311 - San Antonio
  • Texas Oncology - San Antonio Medical Center /ID# 211510 - San Antonio
  • Texas Oncology - Northeast Texas /ID# 213908 - Tyler

Colorado

  • Colorado Blood Cancer Institute /ID# 212800 - Denver
  • Rocky Mountain Cancer Centers /ID# 211508 - Lone Tree

South Carolina

  • Charleston Oncology, P.A. /ID# 211471 - Charleston
  • Prisma Health Cancer Inst - Eastside /ID# 211466 - Greenville

Tennessee

  • Tennessee Oncology - Chattanooga / McCallie /ID# 212717 - Chattanooga
  • Tennessee Oncology-Nashville Centennial /ID# 210944 - Nashville

Arizona

  • Arizona Oncology Associates, PC-HOPE /ID# 211509 - Tempe

Indiana

  • Fort Wayne Medical Oncology /ID# 223523 - Fort Wayne

Minnesota

  • Minnesota Oncology Hematology, PA /ID# 212837 - Minneapolis

Ohio

  • Oncology Hematology Care, Inc. /ID# 212779 - Cincinnati

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2019-08-15
Est. Completion 2022-03-14
Phase Phase 3

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03941964

The ClinicalTrials.gov registry entry for NCT03941964 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT03941964 reports 16 study locations spanning 9 distinct geographic areas - top geographies include Texas, Colorado, South Carolina.

Frequently Asked Questions

What is clinical trial NCT03941964 about?

NCT03941964 is a clinical study titled "A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy". A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with AML who are ineligible for intensive chemotherapy.

What is the current status of trial NCT03941964?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2019-08-15. Estimated completion is 2022-03-14.

What conditions does trial NCT03941964 study?

This clinical trial studies the following conditions: Cancer, Acute Myeloid Leukemia (AML).

What interventions are being tested in trial NCT03941964?

The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Decitabine (DRUG).

Who is sponsoring clinical trial NCT03941964?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03941964 being conducted?

This trial has 16 study locations across Arizona, Colorado, Indiana, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Acute Myeloid Leukemia (AML)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.